Brought to you by 
Aniona APS licenses ion channel ataxia program to Ataxion; Later Updates Deal Terms
26 Jan 2021
Executive Summary
Danish start-up Aniona APS (drugs targeting ion channels) licensed all rights to its ion channel ataxia program to recently formed Atlas Ventures start-up Ataxion Inc. (orphan neurological disorder therapeutics).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aniona APS licenses ion channel ataxia program to Ataxion; Later Updates Deal Terms
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice